The Prognostic Significance of XXXX Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.

@entity1 @entity3012 @entity4022 @entity1721 @entity534 @entity418 @entity3 @entity10008
Purpose: The purpose of this study is to investigate the role of @entity10008 ( @entity10008 ) polymorphism in @entity418 after chemoradiotherapy (CRT). Materials and Methods: Peripheral blood samples from 244 @entity1 treated with CRT for @entity1721 were assessed for the role of @entity10008 genotype on treatment response and survival. Results: A total of 94 @entity1 were homozygous for the @entity4022 388 allele, and 110 were heterozygous and 40 homozygous for the @entity534 388 allele. No significant association was found between the @entity10008 genotype and clinicopathological parameters. However, @entity1 carrying the @entity4022 388 allele showed a better overall response rate than @entity534 388 carriers (p = 0.038). In addition, @entity4022 388 allele @entity1 at an earlier stage showed better @entity3012 and PFS than @entity534 388 carriers. Among these, the @entity4022 388 allele showed significantly improved @entity3012 compared to @entity534 388 carriers in the lymph node (LN) @entity3 group (p = 0.042) compared to the no LN @entity3 group (p = 0.125). However, similar survival outcomes were observed for advanced-stage disease regardless of genotype. Conclusion: This result suggests that the role of @entity10008 Gly388 in treatment outcomes differs according to @entity418 stage. It showed a predictive role in the response of @entity418 @entity1 to CRT with a better trend for @entity3012 in @entity4022 388 than @entity534 388 carriers in the early stages. In particular, LN-positive early-stage @entity1 carrying the @entity4022 388 allele showed improved @entity3012 compared to those carrying @entity534 388.
